The effects of Vericiguat combined with ARNI, BB, MRA, SGLT2i on the cardiac function of DCM HFrEF patients (n = 22) were compared before and after 1 month of treatment: LVEF (32.1% ± 5.9% vs. 39.3% ± 8.1%, P < 0.01); LVEDD (65.8 ± 7.8 vs. 62.3 ± 7.8 mm, P < 0.01); NT-proBNP (2,475.1 ± 2,803.3 vs. 894.9 ± 1,655.7 ng/L, P < 0.01), as shown in Figure 6. Here, NPPB is linked to familial dilated cardiomyopathy.